Is Anamorelin a targeted drug or a chemotherapy drug?

Anamorelin (Anamorelin) is not a targeted drug or a chemotherapy drug, but a non-hormonal selective hunger receptor mimetic. Its mechanism of action is to stimulate appetite by simulating hunger receptors in the brain, thereby increasing the patient's interest in food, promoting food intake, and improving body weight and muscle mass.

Targeted drugs usually act selectively on tumor cells or their surrounding microenvironment by interfering with specific molecules or pathways to inhibit the growth and spread of tumors. Typical targeted drugs include tyrosine kinase inhibitors, anti-angiogenic agents, etc., which are designed to more precisely intervene in the abnormal growth and differentiation of cancer cells.

Unlike this, anamorelin does not directly target cancer cells, but instead modulates patients' appetite and promotes weight gain to alleviate weight loss caused by muscle-wasting diseases. Its main area of u200bu200bapplication is in the treatment of muscle wasting diseases such as weight loss caused by cancer. Therefore, it tends to be more of a supportive treatment to help improve the patient's overall nutritional level and quality of life.

Compared with chemotherapy drugs, anamorelin does not achieve its effect by directly affecting the DNAsynthesis or cell division of cancer cells. The mechanism of action of chemotherapy drugs is usually to interfere with the life cycle of cells and inhibit the proliferation of cancer cells. Therefore, anamorelin is significantly different from chemotherapy drugs in terms of pharmacology and mechanism of action.

Anamorelin is not yet available in the country, so patients cannot purchase it domestically and need to purchase it through overseas channels. There are only original Anamorelin drugs available abroad, mainly from Japan, and the price is around more than 6,000 yuan.